On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 LINZESS® (linaclotide) EUTRx prescription demand growth of 8% year-over-year; in line with full-year expectations Exploring strategic alternatives to maximize stockholder value BOSTON / May 07, 2025 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and... Read More